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Background: Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal
Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in PML diagnosis
is still under-investigated. The aim of the current study is to investigate the cognitive deficits at PML diagnosis in a
group of Italian patients with PML.
Methods: Thirty-four PML patients were included in the study. The demographic and clinical data, the lesion load and
localization, and the longitudinal clinical course was compared between patients with (n = 13) and without (n = 15)
cognitive deficit upon PML suspicion (the remaining six patients were asymptomatic). Clinical presentation of cognitive
symptoms was described in detail.
Result: After symptoms detection, the time to diagnosis resulted to be shorter for patients presenting with cognitive
than for patients with non cognitive onset (p = 0.03). Within patients with cognitive onset, six patients were presenting
with language and/or reading difficulties (46.15%); five patients with memory difficulties (38.4%); three patients with
apraxia (23.1%); two patients with disorientation (15.3%); two patients with neglect (15.3%); one patients with object
agnosia (7.7%), one patient with perseveration (7.7%) and one patient with dementia (7.7%). Frontal lesions were less
frequent (p = 0.03), whereas temporal lesions were slightly more frequent (p = 0.06) in patients with cognitive deficits.
The longitudinal PML course seemed to be more severe in cognitive than in non cognitive patients (F = 2.73, p = 0.03),
but differences disappeared (F = 1.24, p = 0.29) when balancing for the incidence of immune reconstitution syndrome
and for other treatments for PML (steroids, plasma exchange (PLEX) and other therapies (Mefloquine, Mirtazapine,
Maraviroc).
Conclusion: Cognitive deficits at PML onset manifest with symptoms which are absolutely rare in MS. Their
appearance in MS patients should strongly suggest PML. Clinicians should be sensitive to the importance of
formal neuropsychological evaluation, with particular focus on executive function, which are not easily detected
without a formal assessment.
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Progressive multifocal leukoencephalopathy (PML) is an
uncommon brain disease emerging in the setting of im-
mune deficiency [1], caused by the reactivation of the
John Cunningham virus (JCV) in the brain. Despite
widely studied in HIV patients [1], in the last decade
PML has also been observed in Multiple Sclerosis (MS)
patients treated with Natalizumab (NTZ) [2]. Critically,
the infection is present in the brain before the occur-
rence of the first clinical symptoms [3, 4], thus a delay in
PML recognition and Natalizumab cessation can often
occur. Furthermore, due to the relative lack of specificity
in PML related neurological symptoms, the occurrence
of new focal deficits can be misinterpreted as a MS
relapse. As rapid immune reconstitution by removal of
Natalizumab appears to determine prognosis, early diag-
nosis is mandatory [5].
Focal neurological syndromes as well as neuropsycho-
logical deficits are described as presenting symptoms in
PML [3, 6, 7], but the prevalence of specific cognitive dis-
orders as distinctive signs of PML in differential diagnosis
with other MS related cognitive impairments has not been
yet clarified. Dong-Si et al. [8] described 372 PML patients,
who experienced during the course of PML cognitive/be-
havioral or speech symptoms in 75.5% of the cases. How-
ever, these data refer to a later stage of the PML course. In
Clifford et al. [6] series, 57.1% of the patients showed cog-
nitive, behavioral or speech symptoms at PML onset, but
no specifications about the nature of cognitive deficits
were provided by the authors. Finally, Hoepner et al. [7]
showed that, although only half of the patients with PML
complained of cognitive deficits, all of them demonstrated
neuropsychological impairment at formal evaluation, sug-
gesting a higher prevalence of cognitive impairment than
what was subjectively reported. However, the authors did
not consider aphasia as a cognitive deficit, and described
only 8 PML patients, thus limiting the generalizability of
the results. Hence, the importance of cognitive deficits in
PML diagnosis is still underinvestigated.
The current paper describes the neuropsychological
symptoms at onset and the longitudinal clinical course of a
group of Italian MS patients treated with Natalizumab, who
experienced PML, with the aim to better identify the pos-
sible peculiar aspects of PML related cognitive symptoms.
The current study includes 34 Natalizumab treated MS
patients who developed PML between 2009 and 2015 and
were retrospectively collected from 25 Italian MS sites.
Firstly, the whole sample has been analyzed. Secondly, we
focused on patients presenting with cognitive deficits and
compared their demographic and clinical features with
those ones of patients presenting with other symptoms at
PML diagnosis. Moreover, for patients with cognitive symp-
toms at onset, we considered the type of neuropsycho-
logical deficits reported the possible anatomo-clinicalcorrelation between lesion location and the neuropsycho-
logical deficit.Methods
Patients inclusion
An Italian, independent spontaneous collaborative re-
pository initiative made a registry for the collection of
patients with MS treated with NTZ who developed
possible or definite PML according to the American
Academy of Neurology criteria [8], as described in detail
elsewhere [9]. In the current paper, the data from 25
Italian MS Centers, which took part to the initiative
were included, resulting in 34 PML patients who
received diagnosis of definite PML between 2009 and
June 2015. To our knowledge, one NTZ-PML italian
patient with was not included in the registry since
he/she denied his consent for data sharing.
In each Center patients were regularly followed-up,
and their data were retrospectively collected from mem-
bers of the Italian PML group, were included in a
centralized database and were stored by the MS centre
of Montichiari (Brescia). The retrospective analysis of
patients’ data was approved by the ethical committee of
the Spedali Civili of Brescia and was conducted in
accordance with specific national laws and the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments.Data collection
A detailed description of the data collected is present
elsewhere [9]. Here, we only describe the data relevant
for the current paper, extracted from patient charts.
Demographic data included: gender; age at NTZ start;
age at PML diagnosis.
Clinical data included: disease duration (years); previous
immune suppression; total number of NTZ infusions;
annual relapse rate (ARR) in the year before NTZ start and
during NTZ treatment; symptomatic or asymptomatic
PML (i.e. detection of PML lesions at brain MRI scan in
presence or absence of new signs or symptoms respect-
ively); number of JCV-DNA copies detected with quantita-
tive polymerase chain reaction performed on cerebrospinal
fluid sample at PML suspect; clinical symptom (if any)
manifested at PML suspect; diagnosis delay, defined as days
elapsed between the day when the treating neurologist
become aware of the symptomatology and the day in which
cerebrospinal fluid was sampled for JCV search; whether or
not a neuropsychological (NPS) formal assessment has
been performed; longitudinal Expanded Disability Status
scores (EDSS [10]) collected at NTZ start (hereafter
referred as baseline), at PML diagnosis (M0), at 2 months
(M2), 6 months (M6) and 12 months (M12) from PML
diagnosis; whether or not patients were treated with
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(Mefloquine, Mirtazapine, Maraviroc).
Magnetic resonance images (MRI) data included: lesion
patterns classified as unilobar (confined to one lobe), mul-
tilobar (involving two or more contiguous lobes), wide-
spread (involving two or more non-contiguous lobes and/
or present in both hemispheres) [11] and infratentorial [9];
lesion localization; presence or absence of the radiological
features of immune reconstitution inflammatory syndrome
(IRIS) as defined in Prosperini et al. [9].
Statistical analysis
First, we present the data of the whole sample (n = 34).
Secondly, we compared patients with and without
cognitive onset.
Categorical variables are expressed as count (percent-
age) and continuous variables as mean (SD) or median
(range), as appropriated. Between-group differences were
tested using the Chi-squared or the U Mann-Whitney
test/ two independent sample t-tests for categorical and
continuous variables, respectively.
The EDSS scores distribution at all time intervals were
not different from a normal distribution (Kolmogorov-
Smirnov tests, all ps > .20). A repeated measures (RM)
ANOVA with Group (two levels: Cognitive; no Cogni-
tive) as between subjects variable and Time (5 levels:
NTZ beginning; Baseline; M2; M6; M12) as within sub-
jects variable was used in order to compare the longitu-
dinal clinical course of patient with or without cognitive
deficits. Plasma exchange, therapy with steroids and
other therapies (i.e. Mirtazapine, Mefloquine, Maraviroc)
were included in the model as covariates, in order to
remove their effects from the results. Newmann-Keuls
post hoc test was used when necessary.
Results
Whole group analysis (n = 34)
Socio-demographic and clinical data
The 34 patients consisted in ten males and 24 females,
with a mean age of 41.7 ± 9.3 years. The mean EDSS at
PML diagnosis is 4.9 ± 2.0. The mean number of infusions
of NTZ before PML onset was 36.94 ± 17.0 (range 11–78).
Annualized Relapse Rate resulted significantly lower in
the NTZ treatment interval than in the pre NTZ period
(0.13 vs. 1.76, respectively, t = 9.76, df = 66, p < 0.001), con-
firming NTZ efficacy in reducing the progression of the
MS disease in terms of relapses. The mean time elapsed
between the symptoms onset and the PML diagnosis was
50.2 ± 31.4 days. The mean number of viral copies in the
whole sample was 1750 ± 4682 copies/mL, ranging from
10 to 5174 copies/mL with an outlier patient with 26300
viral copies/mL. IRIS emerged in 24 out of 34 patients
(70.5%). The survival rate was 91%: at one-year follow up
31 out of 34 patients were still alive. One patient diedwithin the first 6 months from PML onset due to the
complication of acute acalculous cholecystitis, while two
patients died within 1 year from PML onset due to IRIS
complications. All of them were symptomatic at PML
onset. Twenty-three out of 34 (67.6%) of PML patients
developed IRIS.
Lesion load and localization at PML onset
the MRI scan was available for 31 out of 34 patients. For
the three remaining patients, the MRI scan was acquired
but images were not available and information were
obtained from the neuroradiologist’ s report. Thirteen
(38.2%) patients had a unilobar lesion at PML onset; 9
(26.4%) had multilobar lesions; 6 (17.6%) had widespread
lesions and 6 (17.6%) had infratentorial lesion (cerebellum
or brainstem). Within the encephalic lesions (i.e. exclud-
ing the brainstem lesions, n = 28), occipital lesions were
present in six patients (21.4%), temporal lesions in 12
patients (42.8%), parietal lesions in 11 patients (39.2%),
frontal lesions in 17 patients (60.7%) and diencephalic
lesions in three patients (10.7%). Thus, frontal lesions
were preminent within this cohort of patients.
Clinical presentation of PML
Six patients (17.6%) were asymptomatic, while 28
(82.3%) manifested ≥1 symptom. Within this group, ten
patients (35.7%) presented with pure cognitive symp-
toms; three patients (10.7%) with cognitive and motor
symptoms; six patients (21.42%) with pure motor symp-
toms; three patients (10.7%) with symptoms indicative of
brainstem involvement; two patients (7.14%) with both
motor and brainstem symptoms; two patients (7.14%)
with epilepsy; one patient (3.5%) with visual loss and one
patient (3.5%) with hallucination.
Longitudinal clinical course
The RM ANOVA on longitudinal EDSS scores revealed
a main effect of the variable Time (F[4132] =25.25, p<0.001).
Post hoc tests highlight an EDSS worsening between NTZ
beginning (mean:3.89) and PML onset (4.98, p<0.001), which
is likely to reflect PML insurgence. EDSS at NTZ beginning is
also better than EDSS at the following observations (all
ps < 0.001). EDSS at PML diagnosis (4.98) better than
EDSS at M2 (5.94, p < 0.001), M6 (6.39, p < 0.001) and
M12 (6.04, p < 0.001), while no difference between M2,
M6 and M12 emerged (all ps > 0.21).
Patients with cognitive symptoms at PML onset (n = 13)
Socio-demographic and clinical data
Table 1 presents the comparison between the demo-
graphic and clinical features of PML patients who had a
cognitive symptom at onset (n = 13) and the remaining
patients with a symptomatic onset without cognitive
symptoms (n = 15). The two groups do not differ in any
Table 1 Demographic and clinical features of patients with and
without cognitive deficit at PML diagnosis
Cognitive
onset
No cognitive
onset
n = 13 n = 15 Significance
Gender (♂)a 7 (53.8%) 14 (93.3%) 0.016*
Age at MS diagnosisb 25.6 (11.5) 23.3 (10.3) 0.414
Age at PML diagnosisb 39.0 (14.1) 37.5 (13.8) 0.584
MS duration (years)b 12.9 (7.3) 12.0 (9.6) 0.740
Number of infusions b 33.0 (19.5) 34.5 (20.0) 0.856
Prior Immunesoppressiona 5 (34.7%) 4 (29.4%) 0.505
Viral Loadc 324 [12–26300] 64 [11–4403] 0.271
IRIS insurgence (yes)a 11 (84.6%) 8 (53.3%) 0.077
Steroids administration
(yes)a
12 (92.3%) 14 (93.3%) 0.912
Other therapies (yes)a 8 (61.5%) 10 (66.6%) 0.825
PLEX (yes)a 11 (84.6%) 8 (53.3%) 0.077
Number denotes row number (a), mean (standard deviation) (b) and median
[range] (c). Statistical significance was evaluated using Chi Square (a), two
independent samples t test (b) and Mann Whitney test (c). *asterisk denotes
statistical significance
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der. IRIS, though not significantly, appears to be more
frequent in patients with cognitive onset (p = 0.077).
Plasma Exchange (PLEX) results to be slightly more
frequently administered in patients with cognitive onset
(p = 0.077). Two patients within the cognitive onset and
one patients within the non cognitive onset group died.
Of note, the time elapsed between the symptoms onset
and the PML diagnosis significantly differs between
patients with cognitive onset and patients with non
cognitive onset, being significantly shorter for patients
with cognitive onset (27.5 ± 27.2 days) than for patients
with non cognitive onset (56.6 ± 39.7, two independent
t test = 2.24, df = 26, p = 0.03).Lesion load and localization at PML onset
MRI scan was available for 12 out of 13 patients. For the
remaining patient, MRI was acquired but images were not
available and information were obtained from the neuroradi-
ologist’ s report. Four (30.6%) patients had a unilobar lesion
at PML onset; 5 (38.4%) had multilobar lesions; 3 (23.0%)
had widespread lesions and 1 (7.6%) had infratentorial lesion
(cerebellum). Within the supratentorial lesions, occipital le-
sions were present in four patients (33.3%), temporal lesions
in nine patients (75%), parietal lesions in six patients (50%),
frontal lesions in three patients (25.0%) and diencephalic le-
sions in one patient (8.3%). Interestingly, frontal lesions were
hypo-represented in patients with cognitive onset compared
with the whole cohort (25.0% vs 60.7%, chi square = 4.28, p
= 0.03), whereas temporal lesions were hyper-representedwithin patients with cognitive onset (42.8% vs 75%, chi
square = 3.48, p= 0.06). Lesions are shown in Fig. 1.
Clinical presentation of cognitive PML
Table 2 shows the PML lesion site at MRI, the type of
neuropsychological deficits manifested and/or com-
plained by the patients, the possible anatomo clinical
correlation between the lesion site and the cognitive
deficit. Six patients (46.15%) presented language and/or
reading difficulties (from mild anomia to severe apha-
sia); five patients (38.4%) memory difficulties; three
(23.1%) patients apraxia; two patients (15.3%) disorien-
tation; two patients (15.3%) neglect; one patients (7.7%)
object agnosia, one patient (7.7%) perseveration and
one patient (7.7%) dementia. An at least partial
anatomo-clinical correlation was present in 12/13
patients. Moreover, in the table was also specified how
the symptoms were detected. Formal neuropsycho-
logical (NPS) assessment has been conducted in 10 out
of 13 patients (76.9%). In five out of ten of these cases
we were provided with the NPS tests performed (re-
ported in Table 2), whereas in the remaining five cases,
only a clinical description of the cognitive deficits
manifested by patients was available. In particular, NPS
assessment was performed in seven cases (53.84%)
because of patient’s complaint, in one case (7.7%) upon
observation of neuropsychological symptoms during
the neurological examination, whereas in two patients
(15.3%) the deficits were found during their routing
monitoring.. In the remaining three cases, NPS deficit
was diagnosed basing on patient complaint only (one
case), evidence of the deficit during neurological exam-
ination only (one case) and both patient’s complain and
evidence during neurological examination (one case).
Longitudinal clinical course
The longitudinal clinical course in terms of disability of
patients with and without cognitive symptoms at onset
is shown in Fig. 2. The RM ANOVA on longitudinal
EDSS scores revealed a significant Group x Time inter-
action (F[4104] = 2.73, p = 0.03). Post hoc tests highlight
different clinical course in the two groups. Indeed, in
patients without cognitive impairment at PML onset,
the EDSS at NTZ beginning (mean 4.36) is slightly bet-
ter than the EDSS at PML diagnosis (5.4, p = 0.06), and
is better than the EDSS at M2 (5.83, p = 0.009), M6
(6.36, p < 0.001) and M12 (5.93, p = 0.008). However,
EDSS at PML diagnosis do not differ from EDSS at all
the following observations (all ps > 0.15) and no differ-
ences in EDSS between M2, M6 and M12 emerged
(ps > 0.34). On the contrary, in patients with cognitive
impairment at PML diagnosis, EDSS at NTZ beginning
(mean 3.92) is better than EDSS at PML diagnosis
(5.3, p = 0.009), M2 (6.9, p < 0.001), M6 (7.3, p < 0.001)
Fig. 1 For each patient with cognitive onset is represented the lesion localization and the presenting symptom. The MRI images are available for
12 out of 13 patients. The data of the last patient, reported in Table 2, was derived from the neuroradiologist’s report
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emerged between EDSS at PML diagnosis at EDSS at
M2 (p = 0.008), M6 (p < 0.001) and M12 (p = 0.002).
No differences in EDSS between M2, M6 and M12
emerged (ps > 0.55).
The RM ANOVA was repeated using gender, IRIS
insurgence and PLEX as covariates, in order to remove
their effects on the results. Including these covariates
into the ANOVA, the ANOVA is no more significant
(F[4,92] = 1.24, p = 0.29), i.e. no differences in EDSS
between patients with and patients without cognitive
onset was found.Discussion
Despite the high prevalence of cognitive deficit at PML
diagnosis, their importance on the clinical point of view
and their diagnostic relevance has often been neglected.
In the present observational study, we aimed at describ-
ing the main features of patients presenting with cogni-
tive symptoms, in order to underline the possible
identification of specific symptoms as red flag for PML,
and to compare their clinical course with that oneof
patients presenting with different symptoms at PML
diagnosis. The current paper provides several interesting
findings, namely, the prevalence and type of cognitive
Table 2 Anatomo-clinical correlation and diagnosis details
Lesion site Cognitive deficit Anatomo
clinical
correlation
How symptoms were
detected
Neuropsychological tests
1 L_Parietal Verbal memory X Patient’s complain + formal
NPS assessment
N/A
2 L_Tempo Parietal Language and reading deficits X Evident at neurological
examination
-
3 L_Cerebellum Language deficit, dementia, apraxia - Patient’s complain + formal
NPS assessment
Mini mental state examination;
Language test, apraxia test,
drawing test
4 L_Temporal Aphasia X Evident at neurological
examination + formal NPS
assessment
N/A
5 Bilateral Fronto temporo
and Parietal
Spatial and temporal disorientation +
perseveration + apraxia + left neglect
X Patient’s complain + formal
NPS assessment
Mini mental state examination
for disorientation; Apraxia test;
drawing test; Verbal fluency;
Line bisection
6 L_Parieto occipital Right neglect Objects’
Agnosia
X Patient’s complain + formal
NPS assessment
Line bisection; Apraxia test;
Agnosia test
7 R_ Fronto temporal Memory deficit Disorientation X Patient’s complain -
8 L_Insula, ippocampus
and parahippocampus
(temporal lobe)
Memory deficit X Patient’s complain + formal
NPS assessment
N/A
9 L_Parieto-temporal
occipital
Anomia + semantic paraphasias X Patient’s complain + formal
NPS assessment
Verbal fluency
10 L_Temporo occipital Aphasia, reading difficulties X Patient’s complain + Evident
at neurological examination
-
11 L_Temporo parietal Aphasia, acalculia, apraxia, agraphia X Patient’s complain + formal
NPS assessment
Aachener Aphasia test; Apraxia
test; drawing test; acalculia test
12 L_ Thalamus Memory X formal NPS assessment N/A
13a R_Fronto-temporo occipital Memory and attention X formal NPS assessment N/A
For each patient is reported: the PML lesion site, the type of cognitive deficits manifested and /or complained by the patients, the possible anatomo clinical
correlation between the lesion site and the neuropsychological difficulties and how the symptoms have been diagnosed. athe MRI is missing (neuroradiological
report provided). L left, R right, NPS neuropsychological, N/A not available
Fig. 2 Longitudinal clinical evolution of disability in patients with and without cognitive deficits upon PML suspicion. Bars denotes standard error
of the mean
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the PML lesion localization and the anatomo-clinical
correlation.
13 out of 34 (38.2%) MS patients with Natalizumab
associated PML were presenting with cognitive deficit as
a suggestive symptom of PML onset. This percentage is
lower than the one reported by Clifford et al. [6], who
showed a percentage of 57.1% of cognitive onset, al-
though without any specification of the nature of cogni-
tive deficits. On the other hand, in our sample, though
limited, the symptoms were carefully described at indi-
vidual level and reported mainly as disorders in memory,
attention, neglect, reading, calculation, naming or orien-
tation. Unfortunately, neuropsychological tests were
available for a minority of patients and the performed
test widely differed across patients, thus preventing a
better analysis and interpretation of neuropsychological
tests scores.
Another interesting finding is that the aforementioned
cognitive deficits are not peculiar of MS patients’ cogni-
tive impairment. Indeed, typical cognitive impairment in
MS is described as a general cognitive slowdown and
mainly involves information processing speed, attention,
working memory and executive functions [12, 13], which
are likely to worsen with the disease evolution [14],
typically sparing language and orientation. Furthermore,
neglect, acalculia, apraxia agraphia are notably not pecu-
liar of MS patients. Since these symptoms are absolutely
rare in MS, their appearance in MS patients treated with
NTZ should be considered as a red flag and should give
rise to a suspicion of PML, thus prompting a rapid MR
scan. Indeed, evidences are now available regarding the
positive effects of NTZ on cognitive deterioration of MS
patients over long follow ups, as well as on cognitive im-
provement of MS patients treated with NTZ over time
[15–21]. Furthermore, a rebound of cognitive impair-
ment has also been described following natalizumab dis-
continuation [22]. For these reasons, any new cognitive
symptom emerging during treatment with Natalizumab
should alert the treating neurologist to consider a poten-
tial sign of PML.
Another interesting finding is that amongst the 28
symptomatic PML cases, we observed a shorter time to
diagnosis in patients presenting with cognitive symp-
toms than in those ones presenting with other symp-
toms. We may speculate that cognitive and behavioral
changes, differently from new or worsening motor symp-
toms, alerted clinicians toward a possible PML diagnosis.
Similarly to newly appearing MRI lesions in NTZ treated
patients, any new cognitive symptom or symptoms oc-
curring beyond the first year of treatment should be
considered with suspicion [23]. However, fluctuations of
motor function, which are frequent in patients with MS
and sometimes misinterpreted as MS relapses, couldhave delayed PML diagnosis [24]. Literature data report
that another diagnosis is considered before PML in
nearly two-thirds of PML patients, and that more than
three-quarters of PML patients suffered from diagnostic
delay, irrespective of their underlying immunosuppres-
sive condition [25].
As we reported shorter time to diagnosis in patients
with cognitive presentation compared to those without
cognitive presentation, consequently smallest lesion size,
less viral copies and presumably better prognosis would
be expected in the cognitive onset sample of patients,
which was not the case. The possible interpretation of
this mismatch is that, in our opinion, cognitive deficits’
identification really occurred late in its course, maybe
due to the lack of a careful neuropsychological investiga-
tion and assessment in the majority of the patients. This
may have caused a delay in the “red flag” recognition by
the neurologists and, as a consequence, larger lesions,
more viral copies and worse prognosis in patients with
cognitive presentation. What is worth noting is the need
of sensitizing both physicians and patients toward the
appearance/worsening of cognitive deficit, that might be
also subtle and difficult for the patients to understand
and describe, and for the neurologist to detect, in par-
ticular if related to the frontal lobe.
Furthermore, lesion analysis in PML patients with
cognitive onset revealed that the anatomo-clinical cor-
relation was present in the large majority of cases, even
when the lesion size was small; thus giving strength to
the clinical diagnosis of such cognitive deficit. Similarly
to Richert et al. [11], we also found in the whole PML
group of patients a prevalence of frontal lesions at PML
onset; on the other hand, considering PML patients with
cognitive symptom at onset only, a prevalence in tem-
poral lesions was found. It is possible that some cogni-
tive signs of prefrontal involvement could have been
under-diagnosed by clinicians: noteworthy frontal signs
may be less clinically evident, particularly in the right
hemisphere. It might also be possible that, for this rea-
son, in our patients with PML without cognitive symp-
toms at onset, and even in the asymptomatic one, some
peculiar neuropsychological deficits would have been
present and not clinically detected.
Finally, a careful neuropsychological examination in
MS patients assuming NTZ should be regularly per-
formed, including not only tests measuring attention,
information processing speed and memory, but also ex-
ecutive functions, language, visual exploration and scales
assessing a possible behavioral abnormalities. This could
reveal early cognitive deficits suggestive of PML and
allow the neurologist to quickly obtain MR scans, CSF
sampling for JCV searching and withdrawing natalizu-
mab if a strong suspicion of PML is present. It is worth
noting that formal neuropsychological evaluation with
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measure of cognitive deficits, but also its repetition over
follow up would be able to monitor the evolution of
these deficits over time.
Conclusions
Cognitive deficits at PML onset present with symptoms
that are absolutely rare in MS, such as apraxia, aphasia,
neglect, disorientation. Their appearance should strongly
suggest PML. Clinicians should be sensitized about the
importance of formal neuropsychological evaluation,
with particular focus on executive function, which are
not easily detected without a formal assessment. Patients
should be sensitized as well to tell the doctor every, even
small, change in their clinical status.
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